Back to Search Start Over

Eli Lilly announces details of presentations at ESMO Congress 2023 on October 20-24 in Madrid

Source :
PharmaBiz. October 10, 2023
Publication Year :
2023

Abstract

Eli Lilly and Company has announced that data from studies of Verzenio (abemaciclib; a CDK4/6 inhibitor), Retevmo (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.768374147